The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis
Abstract
BACKGROUND: Brain derived neurotrophic factor (BDNF) is a potent survival factor for motoneurons. This study investigated the safety and tolerability of recombinant methionyl human BDNF (r-metHuBDNF) infused intrathecally by means of an implanted pump in patients with ALS. METHODS: Twenty-five patients with probable or definite ALS were treated with either r-metHuBDNF (25, 60, 150, 400 or 1000 microg/day) or placebo in a 12-week, randomized, double-blinded, sequential, dose-escalation study. Test treatment was interrupted by a washout period from days 11 to 25 to allow the evaluation of laboratory safety measures. In each dose cohort four patients received r-metHuBDNF and one received placebo. On completion of the double-blind period of the study all patients continued to receive r-metHuBDNF in an open-label extension for up to 60 weeks. Lumbar cerebrospinal fluid (CSF) samples were taken periodically from all patients for the measurement of r-metHuBDNF levels and in a minority of patients these were supplemented by cistemal samples. RESULTS: Within days after the initiation of infusion the majority of patients receiving r-metHuBDNF reported mild sensory symptoms, including paraesthesias or a sense of warmth, which were usually confined to the lower limbs and were frequently exacerbated by neck flexion. In most instances these symptoms decreased or even disappeared over several weeks. Sleep disturbance, dry mouth, agitation and other behavioural effects were encountered at higher doses (>150 microg/day) and necessitated dose reductions. The spinal CSF levels of r-metHuBDNF were directly related to dose, with a lumbar to cervical ratio of approximately 4:1. CONCLUSIONS: The intrathecal delivery of r-metHuBDNF in doses of up to 150 microg/day was well tolerated and appears feasible. The reversible CNS effects with higher dose indicate that BDNF can be delivered cranially against CSF flow. The small number of patients and the design of the study did not permit conclusions to be drawn about the efficacy of the treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As growth factors and neurotrophins generally display a poor blood-brain barrier penetration and a short half-life in plasma (Nave et al. 1985; Ochs et al. 2000; Poduslo and Curran 1996)”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Ochs et al. 2000
In the citing paper
“This clinical trial showed that BDNF treatment with doses of 150 mg/day was well tolerated and provided BDNF concentration in CSF that could be neuroprotective, but the number of patients included in the study was too small to make a conclusion about the efficacy of the treatment [106].”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [106]
Citations
Cites
Brooks, B. R. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90191-0 · Cited by 2,140
Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90628-c · Cited by 958 · cited 1×
“Based on cell culture experiments, the high-afnity receptors on motoneurons are expected to be saturated at concentrations higher than 1 ng/ml.(13) Therefore these concentrations should be of physiological signicance, provided that diffusion barriers such as meninges and the perineurium allow signicant penetration…”
BackgroundSendtner, M., Holtmann, B., Kolbeck, R., Thoenen, H., & Barde, Y.-A. (1992) · Nature · doi:10.1038/360757a0 · Cited by 707
Self-citationArrest of Motor Neuron Disease in wobbler Mice Cotreated with CNTF and BDNF
Mitsumoto, H., Ikeda, K., Klinkosz, B., Cedarbaum, J. M., Wong, V., & Lindsay, R. M. (1994) · Science · doi:10.1126/science.8066451 · Cited by 386 · cited 1×
“Ultimately, since BDNF is not likely to cure ALS as a single treatment, combinations of several trophic factors may be necessary.(5,14,15) The effects of r-metHuBDNF on supraspinal centres were the most remarkable ndings in this study.”
BackgroundVentral root avulsion: An experimental model of death of adult motor neurons
Koliatsos, V. E., Price, W. L., Pardo, C. A., & Price, D. L. (1994) · Journal of Comparative Neurology · doi:10.1002/cne.903420105 · Cited by 292
Novikov, L., Novikova, L., & Kellerth, J.-O. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12078-i · Cited by 175
Gravel, C., Götz, R., Lorrain, A., & Sendtner, M. (1997) · Nature Medicine · doi:10.1038/nm0797-765 · Cited by 170 · cited 1×
“Ultimately, since BDNF is not likely to cure ALS as a single treatment, combinations of several trophic factors may be necessary.(5,14,15) The effects of r-metHuBDNF on supraspinal centres were the most remarkable ndings in this study.”
BackgroundSelf-citationThe biological responses of axotomized adult motoneurons to brain- derived neurotrophic factor
Yan, Q., Matheson, C. R., Lopez, O., & Miller, J. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05281.1994 · Cited by 156
The natural history of motoneuron loss in amyotrophic lateral sclerosis
Munsat, T. L., Andres, P. L., Finison, L. J., Conlon, T., & Thibodeau, L. (1988) · Neurology · doi:10.1212/wnl.38.3.409 · Cited by 146
Baumgartner, B. J., & Shine, H. D. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-17-06504.1997 · Cited by 125 · cited 1×
“Ultimately, since BDNF is not likely to cure ALS as a single treatment, combinations of several trophic factors may be necessary.(5,14,15) The effects of r-metHuBDNF on supraspinal centres were the most remarkable ndings in this study.”
Background
Cited by
The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03501.x · Cited by 1,117
“Series of Class IV trials have tested interferon-alfa [106], human recombinant SOD1 [107], ciliary neurotrophic factor [108], brain-derived neurotrophic factor [109] and similar drugs, all without evidence of clinical benefit.”
BackgroundWijesekera, L. C., & Nigel Leigh, P. (2009) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-4-3 · Cited by 442
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
“Clinical trials using intrathecal infusion of BDNF for the treatment of ALS were subsequently performed in small numbers of patients, in an effort to increase the access and duration of the effects of BDNF on motor neurons in the spinal cord; these placebo-controlled trials also failed to demonstrate substantial clini…”
MethodMolecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
“The first clinical trial that explicitly investigated the role of BDNF in neurodegenerative diseases was performed in patients with amyotrophic lateral sclerosis (ALS) (416, 574).”
Background
Metadata
- Authors
- Ochs, G., Penn, R. D., York, M., Giess, R., Beck, M., Tonn, J., Haigh, J., Malta, E., Traub, M., Sendtner, M., & Toyka, K. V.
- Affiliations
- University of Würzburg (DE)
- Rush University Medical Center (US)
- Amgen (United Kingdom) (GB)
- Venue
- Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
- Publisher
- Informa UK Limited
- Published
- 2000-01
- Volume
- 1
- Issue
- 3
- Pages
- 201-206
- ISSN
- 1466-0822 (ISSN-L)
- OpenAlex
- W2022984493
- Cited by
- 302
- References
- 12
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 4 · 2023: 9 · 2022: 17 · 2021: 15 · 2020: 16 · 2019: 17 · 2018: 8 · 2017: 15 · 2016: 18 · 2015: 9 · 2014: 20 · 2013: 18 · 2012: 20
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Keywords
- amyotrophic lateral sclerosis, intrathecal infusion, safety and tolerability, dose escalation, motoneuron survival, cerebrospinal fluid drug concentration, sensory symptoms, sleep disorders, behavioral effects
- MeSH terms
- Adult, Aged, Amyotrophic Lateral Sclerosis, Double-Blind Method, Humans, Injections, Spinal, Middle Aged, Paresthesia, Recombinant Proteins, Sleep Wake Disorders, Smell, Taste, Brain-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1080/14660820050515197
- The paper
- Ochs, G., Penn, R. D., York, M., Giess, R., Beck, M., Tonn, J., Haigh, J., Malta, E., Traub, M., Sendtner, M., & Toyka, K. V. (2000). A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. https://doi.org/10.1080/14660820050515197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.